ABL Diagnostics shareholders approved a dividend of €0.11 per share for the 2025 fiscal year, an increase from €0.05 per share in the 2024 fiscal year. The decision was made at the Annual General Meeting held on June 30, 2026. The higher dividend reflects the company's improved results and strong financial position.

The dividend will be ex-dividend on July 3, 2026, and will be paid on July 7, 2026. The approval was part of a series of resolutions passed by shareholders during the meeting.

ABL Diagnostics specializes in innovative molecular biology tests and global solutions. Its product portfolio includes Molecular polymerase chain reaction (PCR) detection under the UltraGene brand and genotyping by DNA sequencing under the DeepChek® brand.

The company markets its products globally through its own sales team and a network of exclusive distributors. Its customers include academic clinical pathology laboratories, private reference laboratories, and researchers.

ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. The company is headquartered in Woippy and is listed on Euronext in Paris.

Dividend Details

Key Dates

ABL Diagnostics has secured a raised target price of €8.7 from Invest Securities, reflecting strong upside potential based on an accelerated growth trajectory starting in 2026. The analyst reiterated a 'Buy' recommendation, upgrading the target from the previous €8.4 following the company's communication of its financial roadmap. The revised valuation incorporates the ramp-up of growth drivers, an expected improvement in the profitability profile, and the increased contribution of strategic partnerships.

2026 Growth Trajectory

ABL Diagnostics has outlined an ambitious annual trajectory for 2026, targeting revenue of €12.2 million. This represents an increase of 76.5% compared to 2025. The momentum is supported by the recurrence of historical activities in HIV genotyping and software, alongside the ramp-up of new activities integrated in 2025, whose contribution is expected to grow by 93%.

Segment Performance

The growth model is balanced across several engines, with significant variations in expected performance:

Specifically, the kits and reagents segment is driven by HIV growth of 132% and the UltraGene range, which is expected to surge by 353%. This multi-segment positioning is designed to strengthen the visibility and resilience of the business model.

Strategic Catalysts

Invest Securities highlighted several key value creation factors, including a proprietary offering covering tests, software, and services. The company utilizes an 'agnostic platform' approach compatible with major sequencing equipment to limit adoption barriers. New solutions such as HybridChek are expanding the scope of application, while structuring strategic partnerships includes a multi-year contract potentially reaching ~€2.7 million.

Profitability Outlook

The ramp-up in volumes and economies of scale is expected to result in a significant improvement in margins, with increases anticipated in both EBITDA and net income over the period. Despite a constrained in vitro diagnostic market environment, ABL Diagnostics' value proposition is considered sufficiently competitive to support market share gains.